Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $32

Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and lowers the price target from $45 to $32.